Antimutagenic activity of afobazole in various regimens of treatment.
The influence of a new 2-mercaptobenzimidazole derivative afobazole on cytogenetic effects of dioxidine and cyclophosphamide was studied by counting chromosome aberrations in bone marrow cells of C57Bl/6 mice. Afobazole (1-100 mg/kg perorally) exhibited antimutagenic activity determined by its antioxidant properties. This activity depended on the dose and treatment schedule.
Zhanataev
A K
AK
Laboratory of Mutagenesis Pharmacology, Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Durnev
A D
AD
Seredin
S B
SB
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009025:Morpholines / Q000494:pharmacology*; D016877:Oxidants / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D016587:Antimutagenic Agents; D018906:Antineoplastic Agents, Alkylating; D000975:Antioxidants; D001562:Benzimidazoles; D009025:Morpholines; D016877:Oxidants; D011810:Quinoxalines; C001077:dioxidine; C030698:2-mercaptobenzimidazole; D003520:Cyclophosphamide